metformin has been researched along with Gout in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)." | 9.11 | [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005) |
| "The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)." | 7.75 | [Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009) |
| "Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases." | 5.51 | mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019) |
| "To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)." | 5.11 | [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005) |
| " Current data suggest that the mechanism of action of metformin contributes to the development of an anti-inflammatory effect, as well as a decrease in the level of uric acid, and its use can be potentially useful in patients with hyperuricemia and gout." | 4.02 | [Advantages of the use of metformin in patients with impaired uric acid metabolism]. ( Eliseev, MS; Nasonov, EL; Panevin, TS; Zhelyabina, OV, 2021) |
| "We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone." | 3.81 | Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015) |
| "The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)." | 3.75 | [Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009) |
| " Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks." | 2.55 | Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017) |
| "Metformin users were less likely to be involved in accident-related events (adjusted hazard ratio [aHR] 0." | 1.51 | Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes. ( Eskin, M; Eurich, DT; Simpson, SH, 2019) |
| "Gout is the most common inflammatory arthritis worldwide, and patients experience a heavy burden of cardiovascular and metabolic diseases." | 1.51 | mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? ( Broen, JCA; Jansen, M; Merriman, T; Ottria, A; Phipps-Green, A; Radstake, TRDJ; Schuiveling, M; van der Linden, M; van Lochem, E; Vazirpanah, N; Wichers, CGK; Zimmermann, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liao, KF | 1 |
| Hwang, BF | 1 |
| Kuo, YH | 1 |
| Liu, CS | 1 |
| Lai, SW | 1 |
| Eliseev, MS | 3 |
| Panevin, TS | 1 |
| Zhelyabina, OV | 1 |
| Nasonov, EL | 3 |
| Nielsen, SM | 1 |
| Bartels, EM | 1 |
| Henriksen, M | 1 |
| Wæhrens, EE | 1 |
| Gudbergsen, H | 1 |
| Bliddal, H | 1 |
| Astrup, A | 1 |
| Knop, FK | 1 |
| Carmona, L | 1 |
| Taylor, WJ | 1 |
| Singh, JA | 1 |
| Perez-Ruiz, F | 1 |
| Kristensen, LE | 1 |
| Christensen, R | 1 |
| Eskin, M | 1 |
| Simpson, SH | 1 |
| Eurich, DT | 1 |
| Vazirpanah, N | 1 |
| Ottria, A | 1 |
| van der Linden, M | 1 |
| Wichers, CGK | 1 |
| Schuiveling, M | 1 |
| van Lochem, E | 1 |
| Phipps-Green, A | 1 |
| Merriman, T | 1 |
| Zimmermann, M | 1 |
| Jansen, M | 1 |
| Radstake, TRDJ | 1 |
| Broen, JCA | 1 |
| Bruderer, SG | 1 |
| Bodmer, M | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Vitale, A | 1 |
| Cantarini, L | 1 |
| Rigante, D | 1 |
| Bardelli, M | 1 |
| Galeazzi, M | 1 |
| Barskova, VG | 2 |
| Kudaeva, FM | 2 |
| Aleksandrova, EN | 1 |
| Volkov, AV | 2 |
| Nasonova, VA | 1 |
| Bundrick, JB | 1 |
| Litin, SC | 1 |
| Tsapina, TN | 1 |
| Zilov, AV | 1 |
| Iakunina, IA | 1 |
| Il'inykh, EV | 1 |
1 review available for metformin and Gout
| Article | Year |
|---|---|
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Topics: Bariatric Surgery; Diet Therapy; Diuretics; Exercise Therapy; Female; Gout; Humans; Hypoglycemic Age | 2017 |
1 trial available for metformin and Gout
| Article | Year |
|---|---|
[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].
Topics: Adult; Aged; Blood Glucose; Female; Follow-Up Studies; Gout; Humans; Hypoglycemic Agents; Insulin Re | 2005 |
8 other studies available for metformin and Gout
| Article | Year |
|---|---|
Metformin, pioglitazone and gout risk.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gout; Humans; Hypoglycemic Agents; Metformin; | 2022 |
[Advantages of the use of metformin in patients with impaired uric acid metabolism].
Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Hypoglycemic Agent | 2021 |
Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes.
Topics: Administration, Oral; Adult; Asthma; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Ther | 2019 |
mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?
Topics: Cell Death; Cytokines; Gout; Humans; Inflammation; Metformin; Monocytes; Signal Transduction; TOR Se | 2019 |
Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobi | 2015 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2015 |
[Effect of metformin on the clinical course of gout and insulin resistance].
Topics: Adult; Female; Gout; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; | 2009 |
Clinical pearls in general internal medicine.
Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Inf | 2011 |